Atara Q1 net income $38M; FDA lifts EBVALLO holds; $16M offering closes May 16

Atara Biotherapeutics, Inc.

2025-Q1 EPS reported $3.50 revenue$98,149,000

Net income of $38.0M ($3.50 diluted EPS) vs net loss of $31.8M in Q1 2024; revenue $98.1M, up from $27.4M, driven by Pierre Fabre milestone.
Cash $13.8M at Mar 31, 2025; with $16M gross proceeds from May offering, expects runway into Q1 2026.
FDA lifted clinical holds on EBVALLO; Type A meeting Q2 2025 to address CRL; plans to resume Phase 3 ALLELE study.
Workforce reduced ~30% in May, retaining ~23 staff; FY2025 operating expenses expected to decrease ~65% YoY.
James Huang (Panacea) and Nachi Subramanian (Redmile) appointed to board effective after offering close.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James Huang

Director

ATRA · Atara Biotherapeutics, Inc.

Effective: 2025-05-16
Filed: May 15, 2025, 7:59 PM ET

the Board approved the appointment of, to be effective immediately following the completion of the Offering, James Huang and Nachi Subramanian to serve as members of the Board

Appointed

Nachi Subramanian

Director

ATRA · Atara Biotherapeutics, Inc.

Effective: 2025-05-16
Filed: May 15, 2025, 7:59 PM ET

the Board approved the appointment of, to be effective immediately following the completion of the Offering, James Huang and Nachi Subramanian to serve as members of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Huang was appointed as Director at Atara Biotherapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board approved the appointment of, to be effective immediately following the completion of the Offering, James Huang and Nachi Subramanian to serve as members of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Nachi Subramanian was appointed as Director at Atara Biotherapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board approved the appointment of, to be effective immediately following the completion of the Offering, James Huang and Nachi Subramanian to serve as members of the Board

View on SEC.gov

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-120345

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.